Regeneron Pharmaceuticals has been under the limelight with several recent developments. Notably, Morgan Stanley and JPMorgan revised their price targets for the firm, marking downgraded expectations amid selling off from Slow Capital Inc and Greenleaf Trust amongst others. Despite this, Regeneron's FDA approvals for its drugs Libtayo and Evkeeza have been celebrated breakthroughs. Libtayo was greenlit in high-risk CSCC while ongoing trials of Evkeeza show positive results.
Further, Regeneron's robust R&D pipeline, successful late-stage trials such as the Phase 3 Garetosmab trial for a rare disease, and expanded drug approvals have commanded attention. Its stock dipped following FDA's breakthrough approval for Libtayo, but this proved a momentary setback as the stock rose again by 6.9% later.
Regeneron also closed promising deals such as an $80 million agreement for GLP-1/GIP drug rights and was picked by billionaire Mario Gabelli for having huge upside potential. Many investment firms increased their holdings in Regeneron including JB Capital and Callan Family Office. Yet, it is also the subject of a larger short interest, indicating a potential bearish outlook.
Regeneron Pharmaceuticals REGN News Analytics from Wed, 07 May 2025 07:00:00 GMT to Sat, 11 Oct 2025 17:42:43 GMT - Rating 2 - Innovation 7 - Information 5 - Rumor -3
